Cite
HARVARD Citation
Stinchcombe, T. et al. (2022). Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA. Lung cancer. pp. 43-48. [Online].